infographic
HIV Prevention Product Overview
The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.
Accelerating Product Innovation and Availability
Improving how prevention is delivered
Developing a rich pipeline of options for HIV prevention is essential and must be guided by community priorities that define what products are needed and supported through R&D.
Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.
AVAC’s work supports:
- Development of timely, effective and affordable prevention options
- Including community needs and perspectives in R&D
- Getting products faster to market and to scale
- Understanding the products’ users
- Compiling and analyzing market data
- Sharing information
- Bringing effective prevention options to those who need them
- Advocating for the integration of HIV services with sexual and reproductive health
What's New
report
Getting PrEP Rollout Right This Time
Getting PrEP Rollout Right This Time: Lessons from the Field examines key insights from the rollout of oral PrEP and early introduction of injectable CAB and the dapivirine vaginal ring to inform a faster, smarter and more equitable introduction of future HIV prevention tools, including long-acting injectable PrEP, such as lenacapavir.
presentation
HIV Prevention R&D at Risk
AVAC’s analysis of the impact of US Government funding cuts, terminated projects, and other policy changes on the HIV prevention research and development (R&D) pipeline, and on HIV research broadly.
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Related Projects
Dual Prevention Pill Project
Integrating PrEP and contraception in a single pill to expand choices.
PrEPWatch
A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
Coalition to Accelerate Access to Long-Acting PrEP
Overcoming access challenges to new PrEP options.
The Latest on Accelerating Product Innovation
An Overview of Lenacapavir for PrEP Trials
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.
Moving a Product to the Real World
To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.
The HIV Prevention Pipeline
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.